WASHINGTON, DC (April 4) –
“The Association for Accessible Medicines (AAM) and our members who manufacture generic and biosimilar medicines are aligned with the president’s goal of lowering prescription drug prices for patients in the U.S.
We are assessing the proposed tariff list of pharmaceutical ingredients and products by the U.S Trade Representative (USTR) and its possible impact on manufacturing costs for affordable, FDA-approved generic and biosimilar medicines. We are concerned that the proposed tariffs may lead to increased costs of manufacturing for generics and biosimilars and thus higher prescription drug prices for patients in the U.S.
In 2016, our member companies produced over 61 billion doses of generic and biosimilar medicines in the U.S. AAM will maintain a dialogue with USTR to ensure continued patient access to generic and biosimilar medicines.”
ATTRIBUTE TO: Jeff Francer, Senior Vice President & General Counsel